Tumor Markers Reflect Tumor Burden of Pseudomyxoma Peritonei

Mingjian Bai, Shaojun Pang, Yiyan Lu, Hongjiang Wei, Jing Feng, Hounian Zong, Hongbin Xu, Guowei LiangResearch 2021 · DOI

Abstract

Accurate preoperative assessment of tumor burden is critical for planning surgical interventions in patients with pseudomyxoma peritonei (PMP). This study evaluated whether five common serum tumor markers—CEA, CA125, CA 19-9, CA 724, and CA 242—correlate with the Peritoneal Cancer Index (PCI), the standard measure of tumor burden. Analyzing 198 patients, researchers found that all five markers were significantly elevated in high-tumor-burden cases (PCI ≥ 20) and moderately correlated with PCI. These findings suggest that preoperative serum markers can serve as valuable non-invasive indicators to aid surgical planning.

Introduction

Pseudomyxoma Peritonei (PMP) is a rare clinical condition characterized by the progressive accumulation of mucinous ascites and tumor implants throughout the peritoneal cavity. The primary treatment strategy involves cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The success of these procedures often hinges on the preoperative assessment of tumor burden, typically quantified using the Peritoneal Cancer Index (PCI). While imaging techniques like CT and MRI are standard, they can be subjective and sometimes underestimate disease extent. This study investigates the potential of serum tumor markers as objective, accessible proxies for tumor burden.

Methods and Study Population

This retrospective study analyzed data from 198 PMP patients treated at the Aerospace Center Hospital between 2013 and 2021. Patients were categorized into two groups based on their intraoperative PCI: low tumor burden (PCI ≤ 19) and high tumor burden (PCI ≥ 20).

Table 1: Clinicopathological characteristics of the study cohort, including demographics and surgical details.

The researchers measured preoperative levels of five tumor markers: carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), CA 19-9, CA 724, and CA 242. Statistical analyses, including the Mann-Whitney U test and Spearman correlation, were used to evaluate the relationship between these markers and the PCI.

Key Results

The study revealed a clear distinction in marker levels between the two groups. All five markers were significantly higher in patients with a high tumor burden compared to those with a low burden (p < 0.001 for all comparisons).

Table 2: Comparison of serum tumor marker levels between low and high tumor burden subgroups.

Correlation analysis showed that CA 19-9 had the strongest relationship with PCI (r = 0.466), followed by CEA (r = 0.415), CA 724 (r = 0.379), CA 125 (r = 0.372), and CA 242 (r = 0.317). While these correlations are considered moderate, they provide a statistically significant biological signal that reflects the extent of the disease.

Discussion and Clinical Implications

The findings demonstrate that serum tumor markers are biologically linked to the physical extent of PMP. CA 19-9 emerged as the most sensitive marker for reflecting tumor burden in this cohort. Although these blood tests cannot replace the precision of surgical staging or high-quality imaging, they offer a low-cost, non-invasive adjunct for preoperative evaluation.

Integrating these markers into a multi-modal predictive model alongside CT imaging could help clinicians better identify patients who are candidates for radical surgery versus those who might require more conservative debulking. Future research will focus on validating these results in larger, multi-center prospective trials and refining predictive algorithms.

Conclusion

Preoperative serum tumor markers, particularly CA 19-9 and CEA, moderately reflect the tumor burden in PMP patients. Utilizing these markers in clinical practice can contribute to more informed surgical decision-making and improved patient management.

Summary updated

Abstract

Abstract Background: Accurate assessment of preoperative tumor burden contribute to formulate a scientific surgical plan and improve the prognosis of patients with pseudomyxoma peritonei (PMP). Present study aimed to assess whether preoperative serum tumor markers could reflect tumor burden. Methods: A total of 198 PMP patients were included, the peritoneal cancer index (PCI) was employed to reflect tumor burden for PMP patients. All participants were divided into low (PCI ≤ 19) and high (PCI ≥ 20) tumor burden subgroups according to PCI. All serum tumor markers (carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), CA 19-9, CA 724, and CA 242) were compared between the two subgroups. The correlation between tumor markers and PCI will be calculated and compared with each other. Two-sided P value less than 0.05 is considered statistically significant. Results: The level of CEA (ng/ml), CA125 (U/ml), CA 19-9 (U/ml), CA 724 (U/ml), and CA 242 (kU/L) between low and high tumor burden subgroup were [3.35 (1.64, 16.31) vs. 23.12 (8.80, 67.62), Z = -5.381, p&lt;0.001], [19.10 (7.61, 56.95) vs. 72.75 (40.41, 130.55), Z = -5.978, p &lt; 0.001], [6.17 (3.26, 16.22) vs. 45.50 (13.95, 123.61), Z = -5.413, p &lt; 0.001], [7.89 (1.57, 45.10) vs. 84.61 (33.87, 236.93), Z = -5.898, p &lt; 0.001], and [13.32 (3.39, 96.50) vs. 150.00 (102.13, 308.88), Z = -5.166, p &lt; 0.001], respectively. The Spearman correlation between tumor markers and PCI were 0.415 for CEA (p &lt; 0.001), 0.372 for CA 125 (p &lt; 0.001), 0.466 for CA 19-9 (p &lt; 0.001), 0.379 for CA 724 (p &lt; 0.001), and 0.317 for CA 242 (p &lt; 0.001), respectively. Conclusions: Preoperative serum tumor markers could moderately reflect tumor burden for PMP, which may contribute to develop a better surgical plan before operation.
BibTeX
@inproceedings{bai2021tumor,
  author = {Mingjian Bai and Shaojun Pang and Yiyan Lu and Hongjiang Wei and Jing Feng and Hounian Zong and Hongbin Xu and Guowei Liang},
  title = {{Tumor Markers Reflect Tumor Burden of Pseudomyxoma Peritonei}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-691313/v1},
}
Figure